Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.
about
Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationInfluence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipientsMultidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis.Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?Clinical significance of ABCB1 genotyping in oncology.PharmGKB summary: cyclosporine and tacrolimus pathwaysRelationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patientsAssociation of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients.Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results.Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer.The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy.Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation.The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy.Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants.Clinical application of pharmacogenetics in gastrointestinal diseases.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortiumRace, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patientsPharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.Kidney transplantation: current issues and future prospects.Pharmacogenetics may Influence Tacrolimus Daily Dose, but not Urinary Tubular Damage Markers in the Long-Term Period after Renal Transplantation.Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Effect of the C3435T polymorphism of the multidrug resistance 1 gene on the severity of inflammatory bowel disease in Iranian Azeri Turks.Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.Pharmacogenetics of Crohn's disease.ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.
P2860
Q28083875-6DFB97AA-A94A-44BD-BBEE-95668E853B56Q28244228-16CA1B90-98C6-4D64-9498-A11E2B87B01FQ33268368-D28DFBB7-8DD6-4199-B167-2313B8BEDF7FQ33632608-85046574-8F7E-4666-81E8-93BB70149D3AQ33951034-609104CE-A6F5-48E2-AFA2-06D1F51AAEC7Q33989902-ECB52A22-3CAE-4110-A5A4-A762928E6328Q34065305-23F90D34-2A79-4045-8459-79513E038704Q34081393-34CBCD9D-6139-4FFB-A1CF-222A2DEB1FEAQ34278794-A08776E6-EA67-403C-9309-BD92DF09E47EQ34327594-52D7EB18-8BD2-4CF5-BEAF-8BBD3258F744Q34538009-833EB14A-E549-4CB6-8D64-466E9B99D568Q34959857-F1D1F55F-B619-4227-BF98-A272F3CDB0F1Q35071734-BDC338D0-90A7-4FB7-934D-CE7ACCBD85F0Q35544537-F99AA499-4AE8-4426-83A3-A6406F39F7EBQ35666588-0E8C8890-009C-41CF-8933-6DF6E856B59BQ35943046-45FAF9D9-1C51-4EC1-BA9A-0F878C7C9A54Q35968259-8A755B1E-77BF-4776-842D-FD25BEC5BC0BQ35987461-A29AD310-E7D7-4138-8746-366ACEC0689CQ36029868-4C8A4214-CE40-4D14-9D3A-42D18B2AF113Q36120816-9ACBC95B-23DC-4B10-B36E-00216D107D6BQ36120833-E9A94B36-0FB5-42A1-AEAD-7145EFA937DFQ36186945-8E81B234-7365-4857-BBC0-E863B47EAAF4Q36301589-D337ACC9-0C52-4ED3-B1F0-48DC1E75A786Q36326210-48939113-0800-4111-B8B6-58940CF14C3FQ36349672-2CF6BE88-1067-416A-8EC3-CBBDA64662B3Q36379884-A4B56AC9-00A4-4B24-BD31-A0B6B11C229CQ36544981-4B5568C9-DDCB-411D-A281-D92AED52C93BQ36554709-DB016D81-BED1-4C54-8088-07D6D085FC35Q36613862-C67D01ED-7D4B-4CD7-9DE7-CC82730FD5CFQ36630081-8A7BCB94-22C9-4078-B939-768FB3F9C78CQ36761340-98F0EE34-60B2-4524-91CB-E887D99A3501Q36803373-6C42A467-2606-4EFB-94C7-F35564FEAB36Q36916904-CCBC4057-9B39-4CB1-B9C8-7EB69123A263Q36938148-9826C070-F38B-4082-BEBB-E347DB9E97ECQ37041351-C9D87268-A756-455D-B680-BABD78AD7C76Q37074093-DEEA4480-8745-40BF-BFE4-189AFAF03DDBQ37100443-4C3D8800-E66D-4BF2-B8AC-2EC76DF7C6BAQ37157896-A4615401-5149-407A-B02A-14520CB02870Q37205946-6B01FEF1-370C-49DA-B821-28DBC37B04FCQ37211126-C6A70853-CC55-43C0-83FE-50A9D2102092
P2860
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Association of the multidrug r ...... n renal transplant recipients.
@en
Association of the multidrug r ...... n renal transplant recipients.
@nl
type
label
Association of the multidrug r ...... n renal transplant recipients.
@en
Association of the multidrug r ...... n renal transplant recipients.
@nl
prefLabel
Association of the multidrug r ...... n renal transplant recipients.
@en
Association of the multidrug r ...... n renal transplant recipients.
@nl
P2093
P1476
Association of the multidrug r ...... n renal transplant recipients.
@en
P2093
Bruno Cassinat
Christophe Legendre
Céline Verstuyft
Dany Anglicheau
Eric Thervet
Laurent Becquemont
Marie-Hélène Schlageter
P304
P356
10.1097/01.ASN.0000073901.94759.36
P577
2003-07-01T00:00:00Z